论文部分内容阅读
降低血胆固醇和血小板的高反应性是动脉粥样硬化和血栓住心脑血管疾病防治的主要措施。本文探讨了普伐他汀在体外对血小板聚集和血小板血栓烷素Ｂ２（ＴＸＤ２）及环磷酸腺苷（ｃＡＭＰ）含量的影响。血源标本来自２８例高胆固醇血症（ＨＣ）病人和１０例健康体检者。结果显示，ＨＣ病人的血小板功能增强。与加药前比较，不同浓度的普伐他汀（０．０３μｍｏｌ／Ｌ，０．３μｍｏｌ／Ｌ）均可降低ＨＣ组的血小板聚集反应，降低血小板ＴＸＢ２量，增加血小板ｃＡＭＰ量，提示普伐他汀具有抗血小板作用。
Reduce blood cholesterol and platelet hyperresponsiveness is atherosclerosis and thrombosis cardiovascular disease prevention and control of the main measures. This article discusses the effect of pravastatin on platelet aggregation and thromboxane B2 (TXD2) and cAMP content in vitro. Blood samples from 28 patients with hypercholesterolemia (HC) and 10 healthy subjects. The results show that HC patients with enhanced platelet function. Compared with pre-treatment, different concentrations of pravastatin (0.03μmol / L, 0.3μmol / L) could reduce platelet aggregation in HC group, decrease platelet TXB2 and increase platelet cAMP, suggesting that pravastatin has Anti-platelet effect.